Demographic and clinical characteristics at inclusion of individuals with sarcoidosis and their matched general population comparators
| Sarcoidosis | General population | |
| Subjects n | 8737 | 86 376 |
| Age years | 49.8±14.8 | 49.8±14.7 |
| Female | 44.5 | 44.6 |
| Born in non-Nordic country# | 9.5 | 11.8 |
| Education attained years | ||
| ≤9 | 20.6 | 20.8 |
| 10–12 | 49.1 | 46.4 |
| ≥13 | 29.2 | 31.6 |
| Missing | 1.2 | 1.2 |
| History of comorbidity | ||
| Congestive heart disease | 2.4 | 1.3 |
| Atrial fibrillation | 3.2 | 2.1 |
| Acute myocardial infarction | 2.1 | 1.8 |
| Stroke | 1.7 | 1.6 |
| COPD | 2.3 | 1.0 |
| Asthma | 4.6 | 2.4 |
| Hypertension | 21.4 | 15.9 |
| Diabetes mellitus | 7.5 | 4.2 |
| Dyslipidaemia | 10.8 | 8.2 |
| Autoimmune disease | 7.9 | 4.3 |
| Primary immunodeficiency | 0.4 | 0.1 |
| Serious infection in the past year | 3.9 | 0.8 |
| ≥1 medication dispensed in the past 6 months¶ | n=6723 | n=66 441 |
| Systemic corticosteroids | 18.7 | 2.9 |
| Other immunosuppressants+ | 1.2 | 0.7 |
| Hydroxychloroquine | 0.1 | 0.1 |
| Inhaled corticosteroids | 7.3 | 1.9 |
| NSAIDs | 26.3 | 9.7 |
| Antimicrobials§ | 32.6 | 13.2 |
Data are presented as mean±sd or %, unless otherwise stated. Percentages may not sum to 100 owing to rounding. NSAIDs: nonsteroidal anti-inflammatory drugs. #: Nordic countries: Sweden, Denmark, Norway, Finland and Iceland (category excludes missing <0.5%); ¶: ascertained in individuals who entered the cohort starting January 1, 2006 for whom medication dispensations could be obtained from the Prescribed Drug Register; +: includes methotrexate, azathioprine and leflunomide; §: includes antibacterial, antimycobacterial, antifungal and antiviral medications.